(02) 9850 4000
  • Linkedin
  • Twitter
  • Linkedin
  • Twitter
We are Minomic
  • Home
  • Company
    • Management
    • Board
    • Clinical Advisory Panel
    • Shareholder Information
    • Financial Statements
  • For Investors
  • Diagnostics
  • News and Publications
  • Contact Us
Select Page

Industry News: MTPConnect’s COVID-19 Impact Report

by Minomic | Jun 17, 2020

Industry News from MTP
  • Facebook
  • Twitter
  • LinkedIn

Explore the impact of the pandemic lockdown on medtech, biotech and pharma sectors in Australia by downloading MTPConnect’s COVID-19 Impact Report.

PUBLICATIONS

Development and evaluation of the MiCheck test for aggressive prostate cancer. Shore ND, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, et al. Urol Oncol Semin Orig Investig. 2020.

A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population—The MiCheck-01 prospective trial Shore ND, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, et al. Urol Oncol. 2020.

The Role of Glypican-1 in the Tumour Microenvironment. Lund ME, Campbell DH, Walsh BJ. Adv Exp Med Biol. 2020.

Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. Campbell DH, Lund ME, Nocon AL, Cozzi PJ, Frydenberg M, De Souza P, et al. PLoS One. 2018.

Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker. Levin RA, Lund ME, Truong Q, Wu A, Shore ND, Saltzstein DR, et al. Oncotarget. 2018.

Glypican-1 as a biomarker for prostate cancer: Isolation and characterization. Truong Q, Justiniano IO, Nocon AL, Soon JT, Wissmueller S, Campbell DH, et al. J Cancer. 2016.

PATENTS

Minomic Patent Estate

Tweets by MinomicInt

RECENT POSTS

  • Industry News: MTPConnect’s COVID-19 Impact Report
  • Hot Off the Press – Minomic’s MiCheck® Prospective Trial Papers Published
  • Minomic and Sienna enter collaboration agreement to develop pancreatic cancer test
  • Join us for the 4th global summit on precision diagnosis and treatment of prostate cancer

FOR SHAREHOLDERS

Minomic Shareholder Update Q2 2019
Minomic Shareholder Update Q1 2019

Change of Address Form

ANNUAL FINANCIAL STATEMENTS

2019 Annual Financial Statement

MORE INFO

Would you like to talk with Minomic?
Contact Us

ENQUIRIES

Address
Suite 2, Ground Floor, 
75 Talavera Road, 
Macquarie Park, NSW 2113, 
Australia

Phone
International +612 9850 4000
In Australia 02 9850 4000
Compare your time zone with Sydney here

  • Home
  • News and Publications
  • Shareholder Information
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Linkedin
  • Twitter

COPYRIGHT 2020 | MINOMIC - ALL RIGHTS RESERVED